Advertisement
Letter to the Editor|Articles in Press

Understanding and modifying thrombotic risk in patients with myeloproliferative neoplasms

Published:January 31, 2023DOI:https://doi.org/10.1016/j.jjcc.2023.01.007
Understanding and modifying thrombotic risk in patients with myeloproliferative neoplasms
Previous ArticlePrognostic predictors in patients with cardiopulmonary arrest: A novel equation for evaluating the 30-day mortality
Next ArticleAssociation between the number of Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria and clinical outcomes in patients with acute coronary syndrome
      We thank the authors for their interest in our recently published paper [

      Krecak I, Sabljic A, Lucijanic M. Understanding and modifying thrombotic risk in patients with myeloproliferative neoplasms. JCardiol

      ,
      • Leiva O.
      • Jenkins A.
      • Rosovsky R.P.
      • Leaf R.K.
      • Goodarzi K.
      • Hobbs G.
      Predictors of increased risk of adverse cardiovascular outcomes among patients with myeloproliferative neoplasms and atrial fibrillation.
      J Cardiol. 2022; (in press)
      ]. We agree that the pathophysiology of thrombosis in patients with myeloproliferative neoplasms (MPNs) is multifactorial with contribution of non-traditional cardiovascular (CV) risk factors [
      • Leiva O.
      • Hobbs G.
      • Ravid K.
      • Libby P.
      Cardiovascular disease in myeloproliferative neoplasms.
      JACC CardioOncol. 2022; 4: 166-182
      ]. However, the magnitude of the contribution of these risk factors in this patient population (leukocytosis, JAK2 mutational status, etc) on CV and non-CV prognosis is yet to be defined [
      • Mancuso S.
      • Santoro M.
      • Accurso V.
      • Agliastro G.
      • Raso S.
      • Di Piazza F.
      • et al.
      Cardiovascular risk in polycythemia vera: thrombotic risk and survival: can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors?.
      Oncol Res Treat. 2020; 43: 526-530
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. Krecak I, Sabljic A, Lucijanic M. Understanding and modifying thrombotic risk in patients with myeloproliferative neoplasms. JCardiol

        View in Article
        • Leiva O.
        • Jenkins A.
        • Rosovsky R.P.
        • Leaf R.K.
        • Goodarzi K.
        • Hobbs G.
        Predictors of increased risk of adverse cardiovascular outcomes among patients with myeloproliferative neoplasms and atrial fibrillation.
        J Cardiol. 2022; (in press)
        View in Article
        • Leiva O.
        • Hobbs G.
        • Ravid K.
        • Libby P.
        Cardiovascular disease in myeloproliferative neoplasms.
        JACC CardioOncol. 2022; 4: 166-182
        View in Article
        • Mancuso S.
        • Santoro M.
        • Accurso V.
        • Agliastro G.
        • Raso S.
        • Di Piazza F.
        • et al.
        Cardiovascular risk in polycythemia vera: thrombotic risk and survival: can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors?.
        Oncol Res Treat. 2020; 43: 526-530
        View in Article
        • Hermange G.
        • Rakotonirainy A.
        • Bentriou M.
        • Tisserand A.
        • El-Khoury M.
        • Girodon F.
        • et al.
        Inferring the initiation and development of myeloproliferative neoplasms.
        Proc Natl Acad Sci U S A. 2022; 119e2120374119
        View in Article
        • Jaiswal S.
        • Natarajan P.
        • Silver A.J.
        • Gibson C.J.
        • Bick A.G.
        • Shvartz E.
        • et al.
        Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease.
        N Engl J Med. 2017; 377: 111-121
        View in Article
        • Gecht J.
        • Tsoukakis I.
        • Kricheldorf K.
        • Stegelmann F.
        • Klausmann M.
        • Griesshammer M.
        • et al.
        Kidney dysfunction is associated with thrombosis and disease severity in myeloproliferative neoplasms: implications from the German study group for MPN bioregistry.
        Cancers (Basel). 2021; 13
        View in Article
        • Krecak I.
        • Holik H.
        • Martina M.P.
        • Zekanovic I.
        • Coha B.
        • Gveric-Krecak V.
        Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera.
        Int J Hematol. 2020; 112: 377-384
        View in Article
        • Lucijanic M.
        • Galusic D.
        • Krecak I.
        • Sedinic M.
        • Holik H.
        • Perisa V.
        • et al.
        Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis.
        Ann Hematol. 2020; 99: 2779-2785
        View in Article

      Article info

      Publication history

      Published online: January 31, 2023
      Accepted: December 19, 2022
      Received: December 18, 2022

      Publication stage

      In Press Corrected Proof

      Identification

      DOI: https://doi.org/10.1016/j.jjcc.2023.01.007

      Copyright

      © 2023 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX